Biotech Summit

Promise of hot jobs, big growth takes page from Scripps’ script
Promise of hot jobs, big growth takes page from Scripps’ script

Read more on The Palm Beach Post

Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office
BOTHELL, WA–(Marketwire – 08/30/10) – Marina Biotech, Inc. (NASDAQ: MRNA – News ), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company’s proprietary SMARTICLES technology, for delivery …

Read more on Marketwire via Yahoo! Finance

Lupus Researchers Will Examine Ways To Best Apply Findings From Lupus Mouse Model To Human Lupus
Nearly 200 lupus researchers, clinicians and representatives from government, industry, academia and nonprofit organizations involved in lupus research will gather on the campus of the National Institutes of Health to look at ways to best apply research findings from lupus mouse models to human lupus…

Read more on Medical News Today

Two-Year Data from Phase 2 Trial of Genzyme’s Eliglustat Tartrate for Gaucher Disease To Be Published in the Journal …
CAMBRIDGE, Mass.—-Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood.

Read more on Business Wire via Yahoo! Finance

Scientists from JCVI publishes castor bean genome sequence
A research team co-led by scientists from the J. Craig Venter Institute (JCVI) and the Institute for Genome Sciences (IGS), University of Maryland School of Medicine, today published the sequence and analysis of the castor bean (Ricinus communis) genome in Nature Biotechnology.

Read more on News-Medical-Net

A novel idea from former lecturer
Ray Harper releases debut book (17/08/2010 10:28:43)

Read more on Bedford Today

Jay Keasling, co-leader of Berkeley Lab’s Helios Project, is a groundbreaking researcher in the new scientific field of synthetic biology. In Helios, he directs the biology program, incorporating a range of approaches to increasing the efficacy and economy of plants and cellulose-degrading microbes to make solar-based fuels. He is a UC Berkeley professor of Chemical and Bioengineering, and founder of Amyris Biotechnologies, a company that was honored as a Technology Pioneer for 2006 by the World Economic Forum. Keasling has succeeded in using synthetic biology to develop a yeast-based production scheme for precursors of the antimalarial drug artemisinin in work funded by the Bill & Melinda Gates Foundation. His talk was presented June 4, 2007.

Product Description
This digital document is an article from San Fernando Valley Business Journal, published by CBJ, L.P. on October 26, 2009. The length of the article is 1370 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Biotech companies: ranked by number of San Fernando Valley employees.(THE LIST)(Company rankings)
Author: Brian DeWolf
Publication: San Fernando Valley Business Journal (Magazine/Journal)
Date: October 26, 2009
Publisher: CBJ, L.P.
Volume: 14 Issue: 22 Page: 14(1)

Article Type: Company rankings

Distributed by Gale, a part of Cengage Learning

Biotech companies: ranked by number of San Fernando Valley employees.: An article from: San Fernando Valley Business Journal

Product Description
This digital document is an article from San Diego Business Journal, published by Thomson Gale on July 16, 2007. The length of the article is 1001 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Mergers, acquisitions leading ‘exit strategy’ for biotech companies: investors: initial public offerings not always best way to cash out.
Author: Katie Weeks
Publication: San Diego Business Journal (Magazine/Journal)
Date: July 16, 2007
Publisher: Thomson Gale
Volume: 28 Issue: 29 Page: 1(2)

Distributed by Thomson Gale

Mergers, acquisitions leading ‘exit strategy’ for biotech companies: investors: initial public offerings not always best way to cash out.: An article from: San Diego Business Journal

Product Description
This digital document is an article from New Hampshire Business Review, published by Business Publications, Inc. on May 21, 2010. The length of the article is 853 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Unlocking the code for federal research grants; federal grants targeted for small business help fund Austin biotech company’s groundbreaking research.(Ambion Inc.)(Applied Biosystems Group.)(Small Business Innovation Research Program )(Company overview)
Author: Christopher Calnan
Publication: New Hampshire Business Review (Magazine/Journal)
Date: May 21, 2010
Publisher: Business Publications, Inc.
Volume: 32 Issue: 10 Page: S18(1)

Article Type: Company overview

Distributed by Gale, a part of Cengage Learning

Unlocking the code for federal research grants; federal grants targeted for small business help fund Austin biotech company’s groundbreaking research.(Ambion … article from: New Hampshire Business Review